BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25048089)

  • 41. Sarcomatoid mesothelioma: future advances in diagnosis, biomolecular assessment, and therapeutic options in a poor-outcome disease.
    Galetta D; Catino A; Misino A; Logroscino A; Fico M
    Tumori; 2016; 102(2):127-30. PubMed ID: 26108245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.
    Remon J; Reguart N; Corral J; Lianes P
    Cancer Treat Rev; 2015 Jan; 41(1):27-34. PubMed ID: 25467107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma.
    Benjamin H; Lebanony D; Rosenwald S; Cohen L; Gibori H; Barabash N; Ashkenazi K; Goren E; Meiri E; Morgenstern S; Perelman M; Barshack I; Goren Y; Edmonston TB; Chajut A; Aharonov R; Bentwich Z; Rosenfeld N; Cohen D
    J Mol Diagn; 2010 Nov; 12(6):771-9. PubMed ID: 20864637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deciphering signaling pathway interplay via miRNAs in malignant pleural mesothelioma.
    Salman A; Abdel Mageed SS; Fathi D; Elrebehy MA; Abulsoud AI; Elshaer SS; Khidr EG; Al-Noshokaty TM; Khaled R; Rizk NI; Elballal MS; Sayed GA; Abd-Elmawla MA; El Tabaa MM; Mohammed OA; Ashraf A; El-Husseiny AA; Midan HM; El-Dakroury WA; Abdel-Reheim MA; Doghish AS
    Pathol Res Pract; 2023 Dec; 252():154947. PubMed ID: 37977032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Malignant pleural mesothelioma: a new standard of care.
    Stahel RA
    Lung Cancer; 2006 Dec; 54 Suppl 2():S9-S14. PubMed ID: 17059852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
    Beckett P; Edwards J; Fennell D; Hubbard R; Woolhouse I; Peake MD
    Lung Cancer; 2015 Jun; 88(3):344-8. PubMed ID: 25863904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Popat S; Baas P; Faivre-Finn C; Girard N; Nicholson AG; Nowak AK; Opitz I; Scherpereel A; Reck M;
    Ann Oncol; 2022 Feb; 33(2):129-142. PubMed ID: 34861373
    [No Abstract]   [Full Text] [Related]  

  • 48. Updates in Management of Malignant Pleural Mesothelioma.
    John A; O'Sullivan H; Popat S
    Curr Treat Options Oncol; 2023 Dec; 24(12):1758-1789. PubMed ID: 37975977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNAs dysregulation in human malignant pleural mesothelioma.
    Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
    J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.
    Ren R; Yin P; Zhang Y; Zhou J; Zhou Y; Xu R; Lin H; Huang C
    Oncotarget; 2016 Dec; 7(51):84851-84859. PubMed ID: 27769044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort.
    Allione A; Viberti C; Cotellessa I; Catalano C; Casalone E; Cugliari G; Russo A; Guarrera S; Mirabelli D; Sacerdote C; Gentile M; Eichelmann F; Schulze MB; Harlid S; Eriksen AK; Tjønneland A; Andersson M; Dollé MET; Van Puyvelde H; Weiderpass E; Rodriguez-Barranco M; Agudo A; Heath AK; Chirlaque MD; Truong T; Dragic D; Severi G; Sieri S; Sandanger TM; Ardanaz E; Vineis P; Matullo G
    Int J Cancer; 2023 Feb; 152(4):725-737. PubMed ID: 36305648
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).
    Raynaud C; Greillier L; Mazieres J; Monnet I; Mastroianni B; Robinet G; Fraboulet G; Dixmier A; Berard H; Lamy R; Letreut J; Lena H; Oliviero G; Botta S; Vergnenegre A; Borget I; Chouaid C
    BMC Cancer; 2015 Nov; 15():857. PubMed ID: 26546402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pleural mesothelioma.
    Astoul P
    Curr Opin Pulm Med; 1999 Jul; 5(4):259-68. PubMed ID: 10407698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Baas P; Fennell D; Kerr KM; Van Schil PE; Haas RL; Peters S;
    Ann Oncol; 2015 Sep; 26 Suppl 5():v31-9. PubMed ID: 26223247
    [No Abstract]   [Full Text] [Related]  

  • 57. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. European guidelines for the management of malignant pleural mesothelioma.
    van Thiel E; van Meerbeeck JP
    Pol Arch Med Wewn; 2010 Dec; 120(12):503-10. PubMed ID: 21178907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
    Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S
    Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Malignant pleural mesothelioma.
    Chen SE; Pace MB
    Am J Health Syst Pharm; 2012 Mar; 69(5):377-85. PubMed ID: 22345416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.